The Alzheimer's Drug Discovery Foundation (ADDF) is committed to the discovery and development of effective drugs to prevent, treat and cure Alzheimer's disease. A full 100% of every dollar donated to us goes directly to fund research programs. To date, we have invested more than $70 million to fund over 450 drug research programs at academic centers and biotechnology companies in 18 countries.
Successes So Far
After the ADDF’s initial seed funding, our grantees have received commitments of over $1.6 billion in follow-on funding from government, pharmaceutical companies and venture capital firms to further their breakthrough drug research. From more than $15.7 million invested in biotech programs, we have received $3.6 million in returns, which we reinvested in drug discovery and development programs.
In 2012, the US Food and Drug Administration (FDA) approved Amyvid™, the first diagnostic test for Alzheimer’s disease. The ADDF seed-funded the research for Amyvid™ from 2000–2004. This successful technology shows how early financial support for high-risk projects can lead to the development of innovative drugs and diagnostics for Alzheimer’s.
Amyvid is the first of the projects we’ve funded to receive FDA approval, but many more are advancing toward human clinical trials. One such project, led by Dr. Tamara Maes at Oryzon Genomics, is studying how epigenetic therapies for cancer can be used to treat Alzheimer’s disease. (Epigenetic therapies repair changes in our genes that lead to disease.) We partnered with Oryzon, a Barcelona-based biotechnology company, to fund the reapplication of its therapies for Alzheimer’s. The team is now completing the testing needed for approval through the FDA’s Investigational New Drug (IND) program, a required step before human clinical trials can begin.
The ADDF continues to provide critical seed funding for the most innovative research across the globe. As our knowledge about Alzheimer’s advances, so do the potential targets for drugs to prevent, treat and cure it. We ensure that these potential breakthroughs get explored and, when results are positive, accelerate through the drug development process as quickly as possible.